Effects of Race/Ethnicity on MS Diagnosis and Treatment
How aware are clinicians that MS should no longer be considered a “White people only” disease? What roles have race and ethnicity been shown to play in MS disease severity and disability progression? What do health care professionals need to know to provide the most effective care for all their patients?
Join Dr. Yujie Wang from the University of Washington and Dr. Kimystian Harrison, a post doctoral fellow at Johns Hopkins University, as they explore these and other questions in this eMultipleSclerosis Review podcast.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
View all episodes
Clinical and Radiologic Features of an MS Prodrome27:11What’s the evidence supporting the existence of an MS prodromal phase — where the biology of the disease has begun but the symptoms typical of MS have not yet appeared? Are there biomarkers to help identify it? Imaging abnormalities? And how can diagnosing a prodrome benefit patients?Join us as we discuss these questions with Dr. Naila Makhani from Yale School of Medicine, in this video podcast issue of eMultipleSclerosis Review.Take our post-test to claim CME credits.Read this podcast's companion newsletter here.
Mitigating MS DMT Infection Risk21:19Clinicians prescribing the increasingly higher efficacy B-cell depletion or S1P modulators therapies — how aware are they of the newer concerns about safety? Which of their patients may be in greater danger of acquiring PML and/or opportunistic infections? The vaccinations commonly recommended for the general population (eg, COVID-19) — do individuals with MS respond differently, and what should clinicians do about it? What do the data say?Join us, as Dr. Le Hua and Dr. Areeba Siddiqui from the Cleveland Clinic’s Lou Ruvo Center for Brain Health explore these questions in this issue of eMultipleSclerosis Review.Take our post-test to claim CME credits.Read this podcast's companion newsletter here.
Delivering High-Quality HIV Care to Cisgender and Transgender Women26:14Why do cisgender and transgender women, and particularly women of color, account for such a disproportionate percentage of HIV infections in the US? Why are so many so reluctant to accept PrEP? What can clinicians do to bridge this critical gap in essential HIV services?These are some of the questions Guest Author Dr. Kathleen McManus, from the Division of Infectious Diseases and International Health at the University of Virginia, discusses in this issue of eHIV Review.Take our post-test to claim CME credits.Read this podcast's companion newsletter here.
Overcoming Barriers to MS Care23:08Too many individuals with MS are not receiving access to the most effective care. Why? What’s behind these disparities? And what can individual clinicians do to help remove the barriers that prevent equitable care for all patients?Join us, as Dr. Dorlan Kimbrough, from the division of Neurology, Multiple Sclerosis, and Neuroimmunology at the Duke University School of Medicine, discusses these topics, in this issue of eMultipleSclerosis Review. Take our post-test to claim CME credits.Read this podcast's companion newsletter here.
Newer NNRTI Agents in Clinical Practice27:40Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barrier to resistance. Which patients is it right for and in which ones should it be avoided?Join us as we discuss Newer NNRTI Agents in Clinical Practice with Dr. Darcy Wooten from the Division of Infectious Disease at the University of California, San Diego, in this issue of eHIV Review.Take our post-test to claim CME credits.To read a companion newsletter click here.
Clinical Opinions: Managing Spasticity in Individuals with MS41:50How burdensome is spasticity for patients with MS? What’s the approach to treatment, and how effective is it? What do patients and clinicians need to know about cannabis-based therapies? These are the key questions Program Director Dr. Michael Kornberg from the Johns Hopkins School of Medicine discusses with guest MS spasticity experts in this second part of this eMultipleSclerosis Review Special Edition. Take our post-test to claim CME credits.To read a companion newsletter click here.
Hepatitis B: Our Current Understanding41:45Hepatitis B. It may not be curable yet, but as our knowledge continues to grow, so does our ability to benefit our patients today as we prepare them for tomorrow. That’s the focus of this Special HBV Edition of eViralHepatitis Review.The first part of this program presented an evidence-based expert commentary by eViralHepatitis Review Program Director Dr. Mark Sulkowski — Professor of Medicine at Johns Hopkins and Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. This second part is an interview providing more in-depth discussions between Dr. Sulkowski and three of medicine’s top CHB experts. Take our post-test to claim CME credits.To read a companion newsletter click here.
MS Risk Factors and Outcomes17:34In her Expert Commentary, Dr. Melanie Ward from West Virginia University’s Rockefeller Neuroscience Institute provided analysis of the newer data describing the modifiable and nonmodifiable risk factors for developing MS and/or increasing the rate of disease progression and disability.Join us for this podcast as Dr. Ward explains how these findings can affect clinical practice to improve overall care of individuals with MS. Take our post-test to claim CME credits.Read this podcast's companion newsletter here.